| Name | Title | Contact Details |
|---|---|---|
Stefan Abele |
Chief Technical Operations Officer | Profile |
Albireo Pharma is a clinical-stage biopharmaceutical company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases, and other liver and gastrointestinal diseases and disorders. Albireo`s lead product candidate, A4250, is directed to treat rare pediatric cholestatic liver diseases and is in Phase 3 development in its initial target indication, progressive familial intrahepatic cholestasis. Albireo`s clinical pipeline also includes two Phase 2 product candidates. Albireo`s elobixibat, approved in Japan for the treatment of chronic constipation, is the first ileal bile acid transporter (IBAT) inhibitor approved anywhere in the world. Albireo was spun out from AstraZeneca in 2008. Albireo Pharma is located in Boston, Massachusetts, and its key operating subsidiary is located in Gothenburg, Sweden.
Forefront Dermatology is a leading dermatology group practice with numerous convenient locations throughout the United States. Find a dermatologist near me today.
True Health (formerly Central Florida Family Health Center) is a non-profit patient-centered medical home that has been serving the Central Florida community since 1977. Our centers, conveniently located throughout Central Florida, aim to bring you ...
Summa Health is one of the largest integrated delivery systems in Ohio. Encompassing a network of hospitals, community health centers, a health plan, a physician-hospital organization, a multi-specialty physician organization, research and multiple foundations, Summa is nationally renowned for excellence in patient care and for exceptional approaches to healthcare delivery. Summa also is a founding partner of the BioInnovation Institute in Akron. For more information, visit www.summahealth.org. Summa Health is an Affirmative Action employer that promotes Equal Employment Opportunity and Diversity for all individuals. Women, veterans, members of minority groups, and individuals with disabilities are encouraged to apply.